🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are on the rise worldwide, with figures suggesting more than 82 million infections each year. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the face of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Health officials are particularly alarmed about the increase in drug-resistant strains. The global health body has listed it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Experts believe that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for drug creation. The non-profit organisation GARDP collaborated with the drug firm Innoviva to develop it.

“This milestone marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Clinical Trial Data and Worldwide Availability

According to findings released by a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This puts it on an comparable level with the typical regimen, which involves two antibiotics. The study enrolled hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of developing nations.

Clinicians on the front lines have voiced positive views. Access to a one-pill regimen of this kind is seen as a "critical tool" for managing the epidemic. This is deemed crucial to alleviate the strain of the illness for patients and to halt the transmission of untreatable gonorrhoea globally.